Terms: = Bone cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
32 results:
1. Rhizochalinin Exhibits Anticancer Activity and Synergizes with EGFR Inhibitors in Glioblastoma In Vitro Models.
Dyshlovoy SA; Hauschild J; Venz S; Krisp C; Kolbe K; Zapf S; Heinemann S; Fita KD; Shubina LK; Makarieva TN; Guzii AG; Rohlfing T; Kaune M; Busenbender T; Mair T; Moritz M; Poverennaya EV; Schlüter H; Serdyuk V; Stonik VA; Dierlamm J; Bokemeyer C; Mohme M; Westphal M; Lamszus K; von Amsberg G; Maire CL
Mol Pharm; 2023 Oct; 20(10):4994-5005. PubMed ID: 37733943
[TBL] [Abstract] [Full Text] [Related]
2. Clinical study of map2k1-mutated Langerhans cell histiocytosis in children.
Yang Y; Wang C; Wang D; Cui L; Li N; Lian H; Ma H; Zhao Y; Zhang L; Liu W; Wang Y; Wu W; Zhang R; Li Z; Wang T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2517-2527. PubMed ID: 34595543
[TBL] [Abstract] [Full Text] [Related]
3. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
4. Tomatidine Alleviates Osteoporosis by Downregulation of p53.
Yu T; Wu Q; You X; Zhou H; Xu S; He W; Li Z; Li B; Xia J; Zhu H; Zhao Y; Yang Y; Chen K
Med Sci Monit; 2020 Apr; 26():e923996. PubMed ID: 32300098
[TBL] [Abstract] [Full Text] [Related]
5. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP; Siret A; Ignacimouttou C; Panchal K; Diop M; Jenni S; Tsai YC; Roos-Weil D; Aid Z; Prade N; Lagarde S; Plassard D; Pierron G; Daudigeos E; Lecluse Y; Droin N; Bornhauser BC; Cheung LC; Crispino JD; Gaudry M; Bernard OA; Macintyre E; Barin Bonnigal C; Kotecha RS; Geoerger B; Ballerini P; Bourquin JP; Delabesse E; Mercher T; Malinge S
Clin Cancer Res; 2020 Jul; 26(13):3307-3318. PubMed ID: 32220889
[TBL] [Abstract] [Full Text] [Related]
6. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Fortin J; Tian R; Zarrabi I; Hill G; Williams E; Sanchez-Duffhues G; Thorikay M; Ramachandran P; Siddaway R; Wong JF; Wu A; Apuzzo LN; Haight J; You-Ten A; Snow BE; Wakeham A; Goldhamer DJ; Schramek D; Bullock AN; Dijke PT; Hawkins C; Mak TW
Cancer Cell; 2020 Mar; 37(3):308-323.e12. PubMed ID: 32142668
[TBL] [Abstract] [Full Text] [Related]
7. Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Amoura Z
Blood; 2020 Apr; 135(16):1311-1318. PubMed ID: 32107533
[TBL] [Abstract] [Full Text] [Related]
8. A Multifunctional Therapy Approach for cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment.
Zhang L; Pattanayak A; Li W; Ko HK; Fowler G; Gordon R; Bergan R
Mol Cancer Ther; 2020 Jan; 19(1):39-51. PubMed ID: 31582531
[TBL] [Abstract] [Full Text] [Related]
9. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via mek1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract] [Full Text] [Related]
10. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.
Guan Z; Lan H; Chen X; Jiang X; Wang X; Jin K
Mol Med Rep; 2017 Oct; 16(4):4784-4790. PubMed ID: 28849200
[TBL] [Abstract] [Full Text] [Related]
11. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
[TBL] [Abstract] [Full Text] [Related]
12. mek1/2 Inhibition Promotes Macrophage Reparative Properties.
Long ME; Eddy WE; Gong KQ; Lovelace-Macon LL; McMahan RS; Charron J; Liles WC; Manicone AM
J Immunol; 2017 Jan; 198(2):862-872. PubMed ID: 28003382
[TBL] [Abstract] [Full Text] [Related]
13. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract] [Full Text] [Related]
14. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.
Ahsan S; Ge Y; Tainsky MA
Oncotarget; 2016 Aug; 7(35):57171-57185. PubMed ID: 27494873
[TBL] [Abstract] [Full Text] [Related]
15. Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway.
Lagares-Tena L; García-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Huertas-Martínez J; Sáinz-Jaspeado M; Mateo-Lozano S; Rodríguez-Galindo C; Rello-Varona S; Herrero-Martín D; Tirado OM
Oncotarget; 2016 Aug; 7(35):56889-56903. PubMed ID: 27487136
[TBL] [Abstract] [Full Text] [Related]
16. Synergistic cooperation between ABT-263 and mek1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract] [Full Text] [Related]
18. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract] [Full Text] [Related]
19. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and mek1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
[TBL] [Abstract] [Full Text] [Related]
20. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract] [Full Text] [Related]
[Next]
